Trials / Completed
CompletedNCT02570191
A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)
An Open-label, Multicenter, National, Not-randomized Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (40 KD) (PEGASYS) in Patients With HBeAg-negative Chronic Hepatitis B
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy, safety, and tolerability of PEGASYS in participants with HBeAg-negative chronic HBV. The anticipated time on study treatment is 48 weeks, and the target sample size is 60 individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peginterferon alfa-2a | 180 uG in 0.5 mL solution administered once weekly for 48 weeks |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2007-02-01
- Completion
- 2007-02-01
- First posted
- 2015-10-07
- Last updated
- 2016-11-02
Locations
8 sites across 1 country: Bulgaria
Source: ClinicalTrials.gov record NCT02570191. Inclusion in this directory is not an endorsement.